Hengrui Medicine: Remazolam Tosylate for Injection Obtained Clinical Trial Notice

Hengrui Medicine announced that the company and its subsidiary Shanghai Hengrui Medicine Co., Ltd. recently received the “Clinical Trial Notice” approved by the State Drug Administration.

Hengrui Medicine announced that the company and its subsidiary Shanghai Hengrui Medicine Co., Ltd. recently received the “Clinical Trial Notice” approved by the State Drug Administration.

The drug name is Rimazoram Tosylate for Injection.

Rimazoram tosylate for injection is a short-acting GABAA receptor agonist. The indication for this approval is fiberoptic bronchoscopy for sedation.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/16/hengrui-medicine-remazolam-tosylate-for-injection-obtained-clinical-trial-notice/.

Leave a Reply

Please Login to Comment